spacer
home > ebr > summer 2004 > editor's letter
PUBLICATIONS
European Biopharmaceutical Review

Editor's Letter

As we bring you the summer issue of EBR, there appear to be guarded grounds for continued optimism towards an upswing in the European biotechnology industry. As evidenced by the upbeat mood of the US industry at the recent Annual BIO Convention, this new optimism seems to be based on tangible measures of an industry regaining its feet. For example, increasing numbers of biologic drugs (25 out of 37) approved by the FDA in 2003, coupled to decreasing product review timeframes by the FDA, led to renewed investor interest and the second most successful financing year in the US industry's history in 2003 ($19 billion in public and private funds). However, the situation in Europe isn't quite that rosy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Helen Abbott, Technology Consultant at London Technology Network
spacer
Dr Helen Abbott
spacer
spacer
spacer
Lucy George
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Mr Turhan Ozen Chief Cargo Officer at Turkish Airlines elected to the International Air Cargo Association (TIACA) Committee

Turhan Ozen, serving as Chief Cargo Officer at the global brand Turkish Airlines, was elected to the International Air Cargo Association (TIACA) Committee, the joint voice of the industry that aims to enhance the air cargo profile with intensive efforts towards the global standards.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement